Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 2191 AL 2205

Magnetic resonance imaging in Parkinson's disease: from routine imaging to molecular biomarkers - an update for radiologists

Bociański JW, Dorobek M, Walecki J, Mruk B, Sklinda K.

Pol J Radiol. 2025 Feb 9;91:e58-e67. doi: 10.5114/pjr/213608. eCollection 2026.

Eligibility criteria for the use menopausal hormone therapy (MHT) in women with medical conditions (II): Endometriosis, neurological and autoimmune diseases

MHT Eligibility Criteria Group.

Maturitas. 2025 Apr;195:108208. doi: 10.1016/j.maturitas.2025.108208. Epub 2025 Jan 30.

Unveiling the significance of synaptic proteins in parkinson's pathogenesis: A review

Soni R, Shah J.

Int J Biol Macromol. 2025 Apr;304(Pt 1):140789. doi: 10.1016/j.ijbiomac.2025.140789. Epub 2025 Feb 7.

Potential Risk Factors for Psychosis in Parkinson's Disease: A Review of Cohort and Case-Control Studies

Davydow DS, Okun MS, Pontone GM.

J Geriatr Psychiatry Neurol. 2025 Sep;38(5):311-325. doi: 10.1177/08919887251319558. Epub 2025 Feb 10.

Synthetic strategies and medicinal chemistry perspectives of dual acting carbonic anhydrase modulators with monoamine oxidase and cholinesterase inhibitors

Bindra S, Mostafa EM, Abdelgawad MA, Selim S, Kumar S, Mathew B.

RSC Med Chem. 2025 Feb 6;16(4):1532-1549. doi: 10.1039/d4md00837e. eCollection 2025 Apr 16.

Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review

Rossi M, Schaake S, Usnich T, Boehm J, Steffen N, Schell N, Krüger C, Gül-Demirkale T, Bahr N, Kleinz T, Madoev H, Laabs BH, Gan-Or Z, Alcalay RN, Lohmann K, Klein C.

Mov Disord. 2025 Apr;40(4):605-618. doi: 10.1002/mds.30141. Epub 2025 Feb 10.

Natural drug delivery systems for the treatment of neurodegenerative diseases

Kaspute G, Ramanavicius A, Prentice U.

Mol Biol Rep. 2025 Feb 10;52(1):217. doi: 10.1007/s11033-025-10286-9.

Sulforaphane: An emerging star in neuroprotection and neurological disease prevention

Wu N, Luo Z, Deng R, Zhang Z, Zhang J, Liu S, Luo Z, Qi Q.

Biochem Pharmacol. 2025 Mar;233:116797. doi: 10.1016/j.bcp.2025.116797. Epub 2025 Feb 8.

Kinetics of Amyloid Oligomer Formation

Wei J, Meisl G, Dear AJ, Michaels TCT, Knowles TPJ.

Annu Rev Biophys. 2025 May;54(1):185-207. doi: 10.1146/annurev-biophys-080124-122953. Epub 2025 Feb 10.

Targeting PAAN/MIF nuclease activity in parthanatos-associated brain diseases

Guttman LC, Yang L, Liu M, Dawson VL, Dawson TM.

Adv Pharmacol. 2025;102:1-26. doi: 10.1016/bs.apha.2024.12.001. Epub 2025 Jan 15.

Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology

Nahid S, Saeedi S, Hopkins CR.

Adv Pharmacol. 2025;102:159-209. doi: 10.1016/bs.apha.2024.10.005. Epub 2024 Oct 22.

Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system

Matheoudakis K, O'Connor JJ.

Adv Pharmacol. 2025;102:211-235. doi: 10.1016/bs.apha.2024.10.006. Epub 2024 Oct 18.

Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders

Zhao MM, Yang JJ, Hashimoto K.

Adv Pharmacol. 2025;102:237-266. doi: 10.1016/bs.apha.2024.10.007. Epub 2024 Oct 15.

Neutral sphingomyelinase 2: A promising drug target for CNS disease

Huang M, Stremlau M, Zavras J, Zivko C, Thomas AG, Pietri P, Machairaki V, Slusher BS.

Adv Pharmacol. 2025;102:65-101. doi: 10.1016/bs.apha.2024.10.015. Epub 2024 Oct 28.

Associations of the Adaptive Immune System and Age-Related Macular Degeneration

Stürzbecher L, Strauss O.

Adv Exp Med Biol. 2025;1468:3-7. doi: 10.1007/978-3-031-76550-6_1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias